ORIC · ISSUER CIK 1796280
Oric Pharmaceuticals, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 2 Oric Pharmaceuticals, Inc. insiders reported $0.00 of open-market purchases and $1.5M of sales on SEC Form 4.
↗2 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 5 of 5 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$1.5MInsider selling
−$1.5MNet open-market
Oct 21, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 21, 202617:17 | Oct 20, 2026 | ORIC | Chief Financial Officer | S · Sell10b5-1 | $13.53 | −14,000 | 69,828 | -17% | −$189K | ||
| Oct 21, 202617:17 | Oct 20, 2026 | ORIC | Chief Financial Officer | M · Exercise10b5-1 | $4.36 | +14,000 | 83,828 | +20% | $61K | ||
| Oct 2, 202617:50 | Oct 1, 2026 | ORIC | Director | S · Sell10b5-1 | $12.91 | −6,700 | 38,300 | -15% | −$87K | ||
| Oct 2, 202617:50 | Oct 1, 2026 | ORIC | Director | M · Exercise10b5-1 | $1.60 | +3,500 | 41,800 | +9% | $6K | ||
| Sep 29, 202619:16 | Sep 28, 2026 | ORIC | Chief Financial Officer | S · Sell10b5-1 | $13.53 | −13,400 | 69,828 | -16% | −$181K | ||
| Sep 29, 202619:16 | Sep 28, 2026 | ORIC | Chief Financial Officer | M · Exercise10b5-1 | $4.36 | +13,400 | 83,228 | +19% | $58K | ||
| Sep 25, 202619:59 | Sep 24, 2026 | ORIC | Chief Financial Officer | S · Sell10b5-1 | $13.50 | −600 | 69,828 | -1% | −$8K | ||
| Sep 25, 202619:59 | Sep 24, 2026 | ORIC | Chief Financial Officer | M · Exercise10b5-1 | $4.36 | +600 | 70,428 | +1% | $3K | ||
| Aug 28, 202616:11 | Aug 26, 2026 | ORIC | Chief Financial Officer | S · Sell10b5-1 | $13.69 | −77,000 | 69,828 | -52% | −$1.1M | ||
| Aug 28, 202616:11 | Aug 26, 2026 | ORIC | Chief Financial Officer | M · Exercise10b5-1 | $4.89 | +77,000 | 146,828 | +110% | $377K |